|Bid||56.50 x 400|
|Ask||56.51 x 200|
|Day's range||55.89 - 56.55|
|52-week range||32.83 - 56.55|
|PE ratio (TTM)||22.30|
|Forward dividend & yield||0.95 (1.72%)|
|1y target est||60.40|
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Bagsværd, Denmark, 15 January 2018 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 2 February 2017.
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today an alliance with Novo Nordisk to monitor diabetes patients. “At Novo Nordisk, we strive to empower the worldwide global community so they can better #knowyourrisk, by changing diabetes outcomes.
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
Novo Nordisk said that Belgian biopharmaceutical company Ablynx has rejected its €2.6 billion takeover bid and declined to engage in any discussions on the approach.
COPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders. Ablynx rejected Novo's latest takeover approach and analysts predict the Danish group, whose new chief executive is trying to expand by buying drugs developed by competitors, might face counterbidders and would need to raise its bid. Shares in Ablynx closed up 45 percent at 30.80 euros, above the 30.50 euros per share Novo has offered.
HELSINKI (AP) — Danish drugmaker Novo Nordisk has revised up its offer for Belgian biotech company Ablynx as it looks to find growth opportunities beyond its core business.
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type ...
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
Bagsværd, Denmark, 8 January 2018 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 2 February 2017.
FOR IMMEDIATE RELEASE REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 8 January 2018 - Ablynx NV (Euronext Brussels and Nasdaq: ABLX) ("Ablynx" or the "Company") today confirmed ...
Ablynx NV (Euronext Brussels and Nasdaq: ABLX) ("Ablynx" or the "Company") today confirmed that on December 22, 2017 it received an unsolicited conditional proposal from Novo Nordisk A/S (CSE: NOVO B) (NYSE:NVO) ("Novo Nordisk") to acquire all of the outstanding shares of Ablynx for €28.00 (or approximately $33.66) per share in cash and one Contingent Value Right (CVR) linked to two upcoming material events with total potential cash payments over time of up to €2.50 (or approximately $3.01) per share. The Ablynx Board, with the assistance of financial and legal advisors, and taking into account the interests of all its stakeholders, unanimously concluded that the proposal fundamentally undervalues Ablynx and its strong prospects for continued growth and value creation as it implements its long-term strategic plan of becoming a fully integrated biopharmaceutical company.
Danish pharmaceutical company Novo Nordisk A/S offered as much as 2.6 billion euros ($3.1 billion) in cash to acquire Ablynx NV -- its second run at the maker of treatments for rare bleeding disorders ...
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.